# Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Source: https://onco.cc/trials/nct07449754/  
OnCo record `nct07449754` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cobimetinib in melanoma, run by Hanmi Pharmaceutical Company Limited, now recruiting.

## Summary

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma is a phase 2 interventional study registered as NCT07449754 by Hanmi Pharmaceutical Company Limited, with 45 participants planned, started 2026-02-12 and due to reach its primary completion in 2029-09. Interventions recorded: Belvarafenib, Cobimetinib. Conditions listed: Advanced or Metastatic Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07449754
- Phase: 2
- Setting: A Phase 2, Multicenter, Single-Arm Study of Belvarafenib (HM95573) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
- Sponsor: Hanmi Pharmaceutical Company Limited
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07449754: https://clinicaltrials.gov/study/NCT07449754

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Cobimetinib](https://onco.cc/drugs/cobimetinib/)
- companies: [Hanmi Pharmaceutical](https://onco.cc/companies/hanmi-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07449754.json